Bone Cancer Drugs Market, by Type (Multiple Myeloma, Osteosarcoma, Chondrosarcoma, and Ewing’s Sarcoma), by Treatment Type (Targeted Therapy, Chemotherapy, Radiation Therapy, and Surgery), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, a

Bone Cancer Drugs Market, by Type (Multiple Myeloma, Osteosarcoma, Chondrosarcoma, and Ewing’s Sarcoma), by Treatment Type (Targeted Therapy, Chemotherapy, Radiation Therapy, and Surgery), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing’s sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2021, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2021. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA’s Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.
Key features of the study:
This report provides in-depth analysis of the global bone cancer drug market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bone cancer drug market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market
Detailed Segmentation:
Global Bone Cancer Drug Market, By Type:
Multiple Myeloma
Osteosarcoma
Chondrosarcoma
Ewing’s Sarcoma
Global Bone Cancer Drug Market, By Treatment Type:
Targeted Therapy
Chemotherapy
Radiation Therapy
Surgery
Global Bone Cancer Drug Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Bone Cancer Drug Market, By Region:
North America
Type
Multiple Myeloma
Osteosarcoma
Chondrosarcoma
Ewing’s Sarcoma
Treatment Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Surgery
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
Type
Multiple Myeloma
Osteosarcoma
Chondrosarcoma
Ewing’s Sarcoma
Treatment Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Surgery
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Type
Multiple Myeloma
Osteosarcoma
Chondrosarcoma
Ewing’s Sarcoma
Treatment Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Surgery
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Type
Multiple Myeloma
Osteosarcoma
Chondrosarcoma
Ewing’s Sarcoma
Treatment Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Surgery
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Type
Multiple Myeloma
Osteosarcoma
Chondrosarcoma
Ewing’s Sarcoma
Treatment Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Surgery
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
Type
Multiple Myeloma
Osteosarcoma
Chondrosarcoma
Ewing’s Sarcoma
Treatment Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Surgery
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Advaxis, Inc.
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Cellectar Biosciences, Inc.
OPKO Health, Inc.
Pfizer Inc.
Amgen Inc.
Novartis AG
Eli Lilly and Company
Debiopharm Group
Merck & Co
Bayer AG
Bristol-Myers Squibb Company
Takeda Pharmaceutical
F. Hoffmann-La Roche Ltd
Teva Pharmaceutical
“*” marked represents similar segmentation in other categories in the respective section.